Widely used:Recently Viewed
Clear All
$15.71
$-0.15
(-0.95%)
As on 17-Apr-2025 16:25EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$109 Mln
P/E Ratio
--
P/B Ratio
0.84
Industry P/E
--
Debt to Equity
0.06
ROE
-1.06 %
ROCE
-98.88 %
Div. Yield
0 %
Book Value
6175.13
EPS
-5753.81
CFO
$-496.64 Mln
EBITDA
$-558.35 Mln
Net Profit
$-564.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
| -52.37 | 4.73 | -33.15 | -96.72 | -94.93 | -87.34 | -85.56 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
| -97.35 | -83.58 | -46.67 | -42.31 | -94.68 | -93.53 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without... aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey. Address: 26 Main Street, Chatham, NJ, United States, 07928 Read more
Co-Founder, President, CEO & Chairman
Dr. Seth Lederman M.D.
Co-Founder, President, CEO & Chairman
Dr. Seth Lederman M.D.
Headquarters
Chatham, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tonix Pharmaceuticals Holding Corp (TNXP) stood at $ 163 Mln as on 31-Dec-24
The share price of Tonix Pharmaceuticals Holding Corp (TNXP) is $15.71 (NASDAQ) as of 17-Apr-2025 16:25 EDT. Tonix Pharmaceuticals Holding Corp (TNXP) has given a return of -94.93% in the last 3 years.
Tonix Pharmaceuticals Holding Corp (TNXP) has a market capitalisation of $ 109 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tonix Pharmaceuticals Holding Corp (TNXP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tonix Pharmaceuticals Holding Corp (TNXP) and enter the required number of quantities and click on buy to purchase the shares of Tonix Pharmaceuticals Holding Corp (TNXP).
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey. Address: 26 Main Street, Chatham, NJ, United States, 07928
The CEO & director of Dr. Seth Lederman M.D.. is Tonix Pharmaceuticals Holding Corp (TNXP), and CFO & Sr. VP is Dr. Seth Lederman M.D..
There is no promoter pledging in Tonix Pharmaceuticals Holding Corp (TNXP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | Ratios |
|---|---|
|
Return on equity(%)
|
-106.12
|
|
Operating margin(%)
|
-744.5
|
|
Net Margin(%)
|
-1288.25
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tonix Pharmaceuticals Holding Corp (TNXP) was $0 Mln.
